abiraterone and Neoplasm Metastasis
abiraterone has been researched along with Neoplasm Metastasis in 147 studies
Research
Studies (147)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (0.68) | 29.6817 |
2010's | 109 (74.15) | 24.3611 |
2020's | 37 (25.17) | 2.80 |
Authors
Authors | Studies |
---|---|
Ai, J; Bai, S; Lei, H; Liao, D; Peng, G; Qiu, S; Wei, Q; Xiong, X; Xu, H; Yang, L; Yi, X | 1 |
Blanchet, P; Brureau, L; Gourtaud, G; Roux, V; Sadreux, Y; Senechal, C; Vestris, PG | 1 |
Agarwal, N; Azad, A; Benzaghou, F; Carles, J; Chowdhury, S; Kerloeguen, Y; Kimura, A; McGregor, B; Merseburger, AS; Mohamed, N; Oudard, S; Pal, S; Panneerselvam, A; Saad, F; Soares, A; Wang, F | 1 |
Antonarakis, ES; Arafa, AT; Blader, LR; Engle, J; Jha, G; Ramakrishna, K; Ryan, CJ; Zorko, NA | 1 |
Boegemann, M; Kessel, K; Rahbar, K; Schäfers, M; Schlack, K; Seifert, R; Weckesser, M | 1 |
Artigas, C; Flamen, P; Gil, T; Martinez Chanza, N; Peltier, A; Plouznikoff, N; Sideris, S | 1 |
Anceschi, U; Brassetti, A; Calabrò, F; Cindolo, L; De Nunzio, C; Ferriero, M; Flammia, RS; Gallucci, M; Ghahhari, J; Giacinti, S; Guaglianone, S; Leonardo, C; Mastroianni, R; Schips, L; Simone, G; Tema, G; Tubaro, A; Tuderti, G | 1 |
Balestra, A; Droz-Perroteau, C; Fizazi, K; Fourrier-Reglat, A; Guiard, E; Joly, F; Jove, J; Lacueille, C; Lamarque, S; Moore, N; Oudard, S; Rouyer, M; Tubach, F | 1 |
Condon, B; Liskaser, G; Murphy, DG; Thangasamy, IA | 1 |
Aschelter, AM; De Sanctis, V; Macrini, S; Marchetti, P; Marinelli, L; Osti, MF; Reverberi, C; Tronnolone, L; Valeriani, M | 1 |
Assenholt, J; Hansen, TF; Madsen, JS; Osther, PJS; Zedan, AH | 1 |
Ahmed, ME; Andrews, JR; Bryce, AH; Karnes, RJ; Kwon, E | 1 |
Banna, GL; Basso, U; Benanti, C; Bimbatti, D; De Giorgi, U; Di Quattro, R; Libra, M; Lipari, H; Malatino, L; Pitrè, A; Rundo, F; Schepisi, G; Urzia, V | 1 |
Arenas-Bonilla, AJ; Flores-Martín, JF; Galisteo-Moya, R; Gutiérrez-Tejero, F; Moreno-Jiménez, J; Nieblas-Toscano, D; Ramos-Alaminos, CI; Salas-Moreno, MC; Velarde-Muñoz, C | 1 |
Cookson, MS; Parker, DC | 1 |
Carretero-González, A; Castellano, D; de Velasco, G; Lora, D; Lorente, D; Manneh, R | 1 |
Chen, C; Fang, H; Ge, H; He, H; He, L; Wan, Y; Wang, L; Wang, Y; Wu, Y | 1 |
Alvarez-Madrazo, S; Baillie, K; Bennie, M; Cameron, D; Clarke, J; Crearie, C; Jones, RJ; Kavanagh, K; Keel, A; Kurdi, A; Laskey, J; Morrison, D; Mueller, T; Pan, J; Wu, O | 1 |
Adelman, CA; Agarwal, N; Burgents, J; Chi, KN; de Bono, J; Fizazi, K; Goessl, C; Hussain, M; Kang, J; Kohlmann, A; Mateo, J; Mehra, N; Olmos, D; Saad, F; Sandhu, S; Sartor, O; Shore, N; Thiery-Vuillemin, A; Twardowski, P; Wu, W | 1 |
Csizmarik, A; Keresztes, D; Küronya, Z; Nagy, N; Nyirády, P; Riesz, P; Szarvas, T; Váradi, M | 1 |
George, DJ; Higano, CS; Jiao, X; Kalinovsky, J; Miller, K; Saad, F; Sartor, O; Shore, N; Sternberg, CN; Tangirala, K; Tombal, B | 1 |
Baston, C; Gingu, C; Guler-Margaritis, SS; Preda, A; Sinescu, I | 1 |
Abida, W; Aggarwal, RR; Alumkal, JJ; Attwell, S; Bauman, L; Campeau, E; Feng, FY; Heath, EI; Lakhotia, S; Nanus, DM; Norek, K; Pantuck, AJ; Schweizer, MT; Small, EJ; Snyder, M | 1 |
Hamilou, Z | 1 |
Ahmed, ME; Alamiri, J; Alom, M; Andrews, JR; Haloi, R; Higa, J; Jeffrey Karnes, R; Joshi, V; Kwon, E; Motterle, G; Shah, PH | 1 |
Bensfia, S; Carles, J; Castellano, D; de Bono, J; de Wit, R; Eymard, JC; Facchini, G; Feyerabend, S; Fizazi, K; Geffriaud-Ricouard, C; Helissey, C; Iacovelli, R; Kramer, G; Liontos, M; Melichar, B; Oudard, S; Ozatilgan, A; Poole, EM; Sternberg, CN; Sverrisdóttir, Á; Theodore, C; Tombal, B; Wülfing, C | 1 |
Iwamoto, H; Izumi, K; Kadomoto, S; Kadono, Y; Kano, H; Makino, T; Mizokami, A; Naito, R; Shigehara, K; Shimada, T; Yaegashi, H | 1 |
Clements, S; Descamps, T; Fischer, S; Gillessen, S; Green, A; McWilliam, A; Oing, C | 1 |
Cao, W; He, L; Huang, S; Li, Y; Liu, B; Liu, Y; Long, W; Mai, L; Wu, J; Zhang, Z; Zhou, F | 1 |
Avcı, S; Kırca, M; Ozpolat, B; Soylu, H; Ustunel, I | 1 |
Bothos, J; Cathomas, R; Cho, S; de Bono, JS; Fleming, MT; He, P; Hinrichs, MJ; Liang, M; Martinez, P; Miralles, MS; Petrylak, DP; Rosenbaum, AI; Vashisht, K; Wang, JS; Williams, M; Zhang, Q | 1 |
Anand, M; Antonarakis, ES; Armstrong, AJ; Barnett, ES; Berry, WR; Brown, LC; Carbone, EA; Danila, DC; George, DJ; Giannakakou, P; Gill, A; Gregory, SG; Gupta, S; Halabi, S; Healy, P; Jendrisak, A; Luo, J; Nanus, DM; Scher, HI; Schonhoft, JD; Szmulewitz, RZ; Wenstrup, R; Yang, Q; Zhao, JL | 1 |
Bratt, O; Fode, M; Kistorp, C; Klausen, TW; Lindberg, H; Nolsøe, AB; Palapattu, G; Sønksen, J; Ternov, KK; Østergren, PB | 1 |
Antonarakis, ES; Armstrong, AJ; Barnett, E; Carbone, E; Danila, DC; Dos Anjos, CH; George, D; Gill, A; Gonen, M; Halabi, S; Lu, J; Luo, J; Scher, HI; Schonhoft, JD; Szmulewitz, R; Tagawa, S; Wenstrup, R; Yang, Q; Zhao, JL | 1 |
Aksoy, S; Akyol, F; Guler, OC; Hurmuz, P; Kose, F; Muallaoglu, S; Onal, C; Oymak, E; Ozyigit, G; Tilki, B | 1 |
Bilen, MA; Brown, JT; Carthon, B; Caulfield, S; Kucuk, O; Lafollette, J; Liu, Y; Moore, M; Nazha, B; Russler, G; Smith, KER; Wan, L; Yantorni, L | 1 |
Alibhai, SMH; Breunis, H; Emmenegger, U; Feng, G; Fleshner, N; Gregg, R; Hansen, A; Joshua, A; Timilshina, N; Tomlinson, G; Warde, P | 1 |
Chanu, P; Kotani, N; Sane, R; Wade, JR; Wang, N; Wilkins, J; Winkler, J; Yoshida, K | 1 |
Ai, J; Bai, S; Lei, H; Liao, D; Peng, G; Qiu, S; Xiong, X; Xu, H; Yang, L; Yi, X | 1 |
Balk, SP; Cheng, HH; Chew, F; Kantoff, PW; Kolokythas, O; Marck, BT; Matsumoto, AM; Montgomery, RB; Mostaghel, EA; Nelson, PS; Schweizer, MT; Sharifi, N; Taplin, ME; Yu, EY | 1 |
Alexandre, J; Azoulay-Rutman, E; Blanchet, B; Bonnet, C; Boudou-Rouquette, P; Carton, E; Chah Wakilian, A; Goldwasser, F; Golmard, JL; Huillard, O; Noé, G; Orvoen, G; Thomas-Schoemann, A; Vidal, M; Villeminey, C | 1 |
Antonarakis, ES; Carducci, MA; Chen, Y; Denmeade, SR; Eisenberger, MA; Lu, C; Luber, B; Luo, J; Maughan, BL; Paller, CJ; Pienta, KJ; Silberstein, JL; Taylor, MN; Wang, H; Zhu, Y | 1 |
Carlson, RE; Clark, T; Costello, BA; Dehm, SM; Eckloff, BW; Henzler, C; Hillman, DW; Ho, Y; Hon, T; Huang, H; Jen, J; Jimenez, R; Kohli, M; Lang, JM; Li, Y; Pitot, HC; Quevedo, JF; Sicotte, H; Silverstein, KAT; Sperger, JM; Tan, W; Thai, H; Tseng, E; Van Etten, JL; Vedell, PT; Wang, L; Wieben, ED; Yang, R | 1 |
Borza, T; Caram, MEV; Griggs, JJ; Hollenbeck, BK; Miller, DC; Min, HS; Mukherjee, B; Skolarus, TA | 1 |
Bianchini, D; de Bono, J; Gilman, A; Hall, E; IJzerman, M; Kolinsky, M; Lorente, D; Mateo, J; Mehra, N; Miranda, M; Omlin, A; Payne, H; Perez, R; Pezaro, C; Porta, N; Ravi, P; Rescigno, P; Terstappen, L; Tunariu, N | 1 |
Black, PC; Struss, WJ | 1 |
Boccardo, F; Messina, C; Messina, M | 1 |
Blasi, L; Cicero, G; De Luca, R; Dieli, F; Pavone, C; Pepe, A; Simonato, A | 1 |
Bianchi, E; Caroli, P; Celli, M; Conteduca, V; De Giorgi, U; Fantini, L; Galassi, R; Matteucci, F; Moretti, A; Paganelli, G; Rossi, L; Scarpi, E | 1 |
Culig, Z; Eder, I; Eigentler, A; Handle, F; Heidegger, I; Hoefer, J; Klocker, H; Kroon, J; Leo, A; Ploner, C; Puhr, M; Schaefer, G; Van der Pluijm, G | 1 |
Brown, JS; Cunningham, JJ; Gatenby, RA; Zhang, J | 1 |
Albany, C; Antonarakis, ES; Cao, X; Caram, MV; Chinnaiyan, AM; Cooney, KA; Corn, PG; Daignault-Newton, S; Feng, FY; Hussain, M; Knudsen, KE; Kunju, LP; Lonigro, RJ; Mehra, R; Montgomery, B; Robinson, D; Shevrin, DH; Siddiqui, J; Smith, DC; Stadler, WM; Stein, MN; Tomlins, SA; Twardowski, PW; Whang, YE; Wu, YM | 1 |
Folkvaljon, Y; Franck Lissbrant, I; Hjälm-Eriksson, M; Lambe, M; Robinson, D; Stattin, P; Törnblom, M; Ventimiglia, E | 1 |
de Bono, JS; Sartor, O | 1 |
Antonarakis, ES; Chen, Y; Isaacs, WB; Lai, Z; Liang, C; Lu, C; Luber, B; Luo, J; Piana, D; Silberstein, JL; Wang, H | 1 |
Elkon, JM; Lin, J; Millado, KF; Millett, RL | 1 |
Gourdin, T | 1 |
Bianchini, D; Crespo, M; de Bono, JS; Dolling, D; Figueiredo, I; Flohr, P; Lorente, D; Mateo, J; Miranda, S; Olmos, D; Scher, HI; Seed, G; Terstappen, LWMM | 1 |
Aguiar, P; Haaland, B; Lopes, G; Tan, PS | 1 |
Ali, R; Chambers, C; Ghosh, S; North, S; Sawyer, M; Shivji, A | 1 |
Dowsett, M; Folkerd, E; Johnston, SR; Liccardi, G; Martin, LA; Nikitorowicz-Buniak, J; Pancholi, S; Ribas, R; Simigdala, N | 1 |
Fizazi, K; Hamilou, Z; Saad, F | 1 |
Akaza, H; Buchan, NC; Chiong, E; Chung, BH; Davis, ID; Kanesvaran, R; Khochikar, M; Le Chuyen, V; Letran, J; Lojanapiwat, B; Murphy, DG; Ng, CF; Ong, T; Pu, YS; Saad, M; Schubach, K; Türkeri, L; Umbas, R; Williams, S; Ye, DW | 1 |
Arranz Arija, JA; Bracarda, S; Chan, WY; de Bono, JS; De Giorgi, U; Font, A; Gendreau, S; Jinga, V; Ma, H; Maslyar, DJ; Massard, C; Patel, PH; Radavoi, GD; Riisnaes, R; Rodrigues, DN; Shih, KC; Xu, N | 1 |
Saad, F | 1 |
Barret, E; Bennamoun, M; Bonnetain, F; Cathala, N; Cathelineau, X; Charton, E; Fenioux, C; Henriques, J; Joulia, ML; Louvet, C; Molitor, JL; Mombet, A; Prapotnich, D; Ropert, S; Rozet, F; Sanchez-Salas, R | 1 |
Brown, JS; Cunningham, JJ; Gatenby, RA; Staňková, K | 1 |
Chi, KN; Eigl, BJ; Finch, DL; Gleave, ME; Ivanov, N; Khalaf, DJ; Kollmannsberger, CK; Oja, C; Sunderland, K; Vergidis, J; Zulfiqar, M | 1 |
Carles, J; Gillessen, S; Heidenreich, A; Heinrich, D; Keizman, D; Miller, K; Nilsson, S; O'Sullivan, JM; Reeves, J; Saad, F; Seger, M; Wirth, M | 1 |
Attard, G; Casadio, V; Castro, E; Conteduca, V; De Giorgi, U; Farolfi, A; Gonzalez-Billalabeitia, E; González-Del-Alba, A; Gurioli, G; Hernando, S; Jayaram, A; Lolli, C; Marin-Aguilera, M; Maugeri, A; Medina, A; Mellado, B; Morales-Barrera, R; Olmos, D; Puente, J; Rodriguez-Vida, A; Romero-Laorden, N; Salvi, S; Scarpi, E; Schepisi, G; Vidal, MJM; Villa-Guzmán, JC; Wetterskog, D; Wingate, A | 1 |
Shao, N; Ye, DW; Zhu, Y | 1 |
James, ND | 1 |
Chen, RC; Choudhury, A; Henry, A; Mistry, H; Mitin, T; Pinkawa, M; Spratt, DE | 1 |
Battaglia, A; De Meerleer, G; Devos, G; Everaerts, W; Joniau, S; Moris, L; Tosco, L; Van den Broeck, T | 1 |
Arasaratnam, M; Bhatnagar, A; Crumbaker, M; Gurney, H; McKay, MJ; Molloy, MP | 1 |
Becker, DJ; Becker, KD; Iyengar, AD; Loeb, S; Makarov, D; Ng, J; Punekar, SR; Zaman, A | 1 |
Hammerer, P; Manka, L | 1 |
Chapin, BF; Ranasinghe, WKB; Reichard, CA | 1 |
Chung, JS; Henderson, J; Hovelson, DH; Morgan, TM; Palapattu, GS; Qiao, Y; Reichert, Z; Singhal, U; Spratt, DE; Taichman, RS; Tomlins, SA; Wang, Y; Zaslavsky, AB | 1 |
Armstrong, CM; Cai, D; Chen, J; Chen, N; Dai, J; Guo, W; Liu, J; Liu, Z; Ni, Y; Nie, L; Shen, P; Sun, G; Yin, X; Zeng, H; Zhang, H; Zhang, M; Zhang, X; Zhao, J; Zhao, P; Zhu, S; Zhu, X | 1 |
Hotte, SJ; Loblaw, DA; Walker-Dilks, C; Winquist, E | 1 |
Arlen, PM; Madan, RA | 1 |
de Wit, R; Fitzpatrick, JM | 1 |
de Morrée, ES; de Wit, R; Mathijssen, RH; Moll, JM; Teubel, W; van Royen, ME; van Soest, RJ; van Weerden, WM; Wiemer, EA | 1 |
Balani, G; Gipson, G; Srinivas, S; Tang, J; Wilson, L; Xiang, P; Yu, D; Zhong, L | 1 |
Bahl, A | 1 |
Altavilla, A; Attard, G; Bianchini, D; de Bono, JS; Ferraldeschi, R; Grist, E; Lorente, D; Mateo, J; Ravi, P; Sideris, S; Smith, A; Wong, S; Zafeiriou, Z | 1 |
Blank, PR; Puri, D; Szucs, TD | 1 |
Labrie, F | 1 |
Bianchi, E; Burgio, SL; Campadelli, E; Carretta, E; Carrozza, F; Conteduca, V; De Giorgi, U; Fabbri, P; Menna, C; Montanari, M; Rudnas, B | 1 |
Bellmunt, J; de Bono, JS; Efstathiou, E; Kheoh, T; Li, J; Loriot, Y; Molina, A; Montgomery, B; Ryan, CJ; Scher, HI; Tran, N | 1 |
Alimohamed, N; Atenafu, EG; Joshua, AM; Knox, JJ; Leibowitz-Amit, R; Seah, JA; Sridhar, SS; Tannock, IF; Templeton, AJ; Vera-Badillo, FE | 1 |
Pal, SK; Sartor, O | 3 |
Auchus, RJ; Mundle, SD; Nguyen, S; Yu, MK | 1 |
Beer, TM; Graff, JN | 1 |
Akaza, H; Imanaka, K; Nakatani, T; Nishiyama, T; Ozono, S; Satoh, T; Tanabe, K; Terai, A; Uemura, H; Yokomizo, A | 1 |
Agarwal, N; Antonarakis, ES; Azad, A; Batten, JA; Cheng, HH; Chi, KN; Galsky, MD; Gulati, R; Heath, EI; Leiter, A; Montgomery, RB; Nadal, R; Pal, SK; Rehman, HT; Twardowski, P; Vaishampayan, UN; Yu, EY | 1 |
Afshar, M; Al-Alloosh, F; James, ND; Pirrie, S; Porfiri, E; Rowan, C | 1 |
Anderson, SA; Azad, AA; Bazov, J; Bell, RH; Chi, KN; Collins, CC; Gleave, ME; Haegert, A; Le Bihan, S; McConeghy, B; Paris, P; Shukin, R; Small, EJ; Thomas, G; Volik, SV; Wang, Y; Wyatt, AW; Youngren, J | 1 |
Attard, G; Bianchini, D; Crespo, M; de Bono, JS; Ferraldeschi, R; Figueiredo, I; Flohr, P; Lorente, D; Miranda, S; Nowakowska, K; Riisnaes, R; Rodrigues, DN; Sideris, S; Terstappen, LW; van Dalum, G; Zafeiriou, Z | 1 |
Angel, C; D'Costa, I; Rischin, D; Solomon, B; Urban, D | 1 |
Bianco, V; Fiaschi, AI; Francini, E; Laera, L; Petrioli, R; Ponchietti, R; Roviello, G | 1 |
Antonarakis, ES; Maughan, BL | 1 |
Crawford, ED; Higano, CS; Hussain, M; Petrylak, DP; Shore, ND | 1 |
Bianco, V; Fiaschi, AI; Francini, E; Francini, F; Laera, L; Petrioli, R; Roviello, G | 1 |
Benoist, GE; Gerritsen, WR; Kramers, C; Mulders, PF; Schers, HJ; van Erp, PH; Westdorp, H | 1 |
Bergman, AM; Bos, MM; Chitu, D; de Morrée, ES; de Wit, R; Goey, SH; Hamberg, P; Mathijssen, RH; Nieuweboer, AJ; van der Meer, N; van Soest, RJ | 1 |
Albiges, L; Antoun, S; Bayar, A; di Palma, M; Escudier, B; Fizazi, K; Ileana, E; Laplanche, A; Loriot, Y; Massard, C | 1 |
Audenet, F; Basset, V; Branchereau, J; de La Taille, A; Flamand, V; Lebdai, S; Lebret, T; Murez, T; Neuzillet, Y; Ploussard, G | 1 |
Alesini, D; Basso, U; Caffo, O; Campadelli, E; Conteduca, V; D'Angelo, A; De Giorgi, U; Donini, M; Ermacora, P; Fratino, L; Gasparro, D; Giordano, M; Lo Re, G; Lolli, C; Maines, F; Massari, F; Messina, C; Procopio, G; Ratta, R; Veccia, A; Verderame, F; Zagonel, V | 1 |
Wadman, M | 1 |
Savage, N | 1 |
Antonarakis, ES; Denmeade, SR; Luber, B; Teply, BA | 1 |
Brasso, K; Røder, MA; Thim, S; Thortzen, A | 1 |
Boegemann, M; Eminaga, O; Herrmann, E; Hinkelammert, R; Krabbe, LM; Mikah, P; Papavassilis, P; Schrader, AJ; Semjonow, A | 1 |
Gschwend, JE; Hatzichristodoulou, G; Heck, MM; Höppner, M; Kübler, H; Luppa, PB; Maurer, T; Nawroth, R; Retz, M; Schmid, SC; Seitz, AK; Tauber, R; Thaler, MA; Thalgott, M | 1 |
Barsová, L; Bartoš, J; Chalupa, J; Dvořák, J; Forster, J; Hejzlarová, V; Holikova, M; Richter, I; Sochor, M; Stankuš, I | 1 |
Divine, GW; Hafron, JM; Hung, J; Hwang, C; Taylor, AR | 1 |
Adamo, V; Barni, S; Boccardo, F; Bruno, M; Caffo, O; Caserta, C; Chiuri, VE; De Giorgi, U; De Vincenzo, F; De Vivo, R; Derosa, L; Dinota, A; Facchini, G; Fratino, L; Grassi, P; Messina, C; Mosca, A; Porcu, L; Procopio, G; Ricotta, R; Santini, D; Scavelli, C; Surace, G; Susi, M; Tartarone, A; Verzoni, E; Zaniboni, A | 1 |
Antoun, J; Bteich, F; Ghosn, M; Jalkh, A; Kourie, HR | 1 |
Baeten, K; Bianchini, D; Crespo, M; Danila, DC; de Bono, JS; Figueiredo, I; Fleisher, M; Flohr, P; Kheoh, T; Lorente, D; Mateo, J; McCormack, R; Miranda, S; Molina, A; Olmos, D; Scher, HI; Seed, G; Terstappen, LW | 1 |
Antonarakis, ES; Eshleman, JR; Frick, KD; Luo, J; Markowski, MC | 1 |
Balk, SP; Bhasin, M; Bubley, GJ; Domachevsky, L; Kantoff, PW; Lis, R; Marck, BT; Matsumoto, AM; McKay, RR; Montgomery, B; Mostaghel, EA; Taplin, ME; Voznesensky, O; Werner, L; Zhang, Z; Zukotynski, KA | 1 |
Biasco, E; Crucitta, S; Danesi, R; Del Re, M; Derosa, L; Falcone, A; Galli, L; Jenster, GW; Miccoli, M; Orlandini, C; Rofi, E; van Schaik, RH | 1 |
Srinivas, NR | 1 |
Aroasio, E; Berruti, A; Bertaglia, V; Buttigliero, C; DI Maio, M; Scagliotti, GV; Tucci, M; Vignani, F | 1 |
Albiges, L; Attard, G; Bianchini, D; de Bono, J; Fizazi, K; Loriot, Y; Massard, C; Mateo, J; Mehra, N; Petrylak, DP; Pezaro, C; Ryan, CJ; Shen, L; Varga, A | 1 |
Cristofanilli, M; Hoffman-Censits, JH; Kelly, WK; Kennedy, B; Kilpatrick, D; Leiby, B; Lewis, N; Lin, J; Mu, Z; Patel, SA; Sama, AR; Yang, H; Ye, Z | 1 |
Aringer, M; Boegemann, M; Krabbe, LM; Rahbar, K; Schlack, K; Schrader, AJ; Semjonow, A; Steinestel, J; Thomes, S | 1 |
Bezrukov, EA; Kondrashina, AV; Rapoport, LM | 1 |
Concepcion, RS; Crawford, ED; Finkelstein, SE; Gomella, LG; Keane, TE; Koo, PJ; O'Sullivan, JM; Petrylak, DP; Saad, F; Shore, N; Sieber, P; Slovin, SF; Stone, NN; Tombal, B; Vogelzang, NJ; Yu, EY | 1 |
Alhasso, A; Ansari, A; Ansari, J; Glaholm, J; Hussain, SA; Mahmood, R | 1 |
Djavan, B; Farr, A; Herout, R; Margreiter, M; Tosev, G | 1 |
Bianchini, D; Cheng, T; Chi, KN; Chieffo, N; Chu, L; de Bono, JS; Efstathiou, E; Ellard, SL; Fizazi, K; Flaig, TW; Fléchon, A; Goodman, OB; Hainsworth, JD; Haqq, CM; Harland, S; Hutson, TE; Jones, RJ; Kheoh, T; Logothetis, CJ; Loriot, Y; Mainwaring, P; Molina, A; North, S; Patterson, H; Ryan, CJ; Saad, F; Saleh, M; Scher, HI; Scholz, M; Staffurth, JN; Sternberg, CN; Zivi, A | 1 |
Antonarakis, ES; Eisenberger, MA | 1 |
Beltran, H; Tagawa, ST | 1 |
Sonpavde, G | 1 |
Berruti, A; Pia, A; Terzolo, M | 1 |
de Bono, JS; Massard, C; Michels, RM; Sartor, O | 1 |
Beatty, J; Bell, R; Miller, M; Mohammed, A; Rawlinson, A | 1 |
Birtle, A | 1 |
Attard, G; Belldegrun, AS; de Bono, JS | 1 |
Reviews
34 review(s) available for abiraterone and Neoplasm Metastasis
Article | Year |
---|---|
Efficacy and safety of bipolar androgen therapy in mCRPC after progression on abiraterone or enzalutamide: A systematic review.
Topics: Androgens; Androstenes; Benzamides; Disease Progression; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Testosterone; Treatment Outcome | 2022 |
The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer.
Topics: Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms | 2020 |
Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis.
Topics: Androstenes; Benzamides; Bibliometrics; Bone Neoplasms; DNA Repair; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Publications; Receptors, Androgen; United Kingdom; United States; United States Food and Drug Administration | 2020 |
Molecular underpinnings of systemic treatment resistance in metastatic castration-resistant prostate cancer
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Treatment Outcome | 2020 |
Systemic treatment options for metastatic hormone-sensitive prostate cancer: making sense of the data.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Hormones; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Treatment Outcome | 2020 |
The evolving options in metastatic castration-sensitive prostate cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 2020 |
Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis.
Topics: Androstenes; Benzamides; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life | 2021 |
Steroid switch after progression on abiraterone plus prednisone in patients with metastatic castration-resistant prostate cancer: A systematic review.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Neoplasm Metastasis; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2021 |
Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!
Topics: Androgen Antagonists; Androstenes; Clinical Decision-Making; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Patient Selection; Progression-Free Survival; Prostatic Neoplasms; Time Factors; Treatment Outcome | 2018 |
Metastatic Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Resistance, Neoplasm; Humans; Male; Mutation; Neoplasm Metastasis; Prostatic Neoplasms | 2018 |
Recent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventions.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic | 2018 |
Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Diphosphonates; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Treatment Outcome | 2018 |
Treatment of hormone-naïve metastatic prostate cancer.
Topics: Androgen Antagonists; Androstenes; Clinical Trials, Phase III as Topic; Docetaxel; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Prospective Studies; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic | 2018 |
Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Asia, Eastern; Asia, Southeastern; Combined Modality Therapy; Consensus; Developing Countries; Docetaxel; Humans; Lymph Node Excision; Male; Neoplasm Metastasis; Oceania; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Risk Factors | 2019 |
Germline DNA-repair Gene Mutations and Efficacy of Abiraterone or Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.
Topics: Androstenes; Benzamides; DNA Repair; Germ Cells; Humans; Male; Mutation; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2019 |
Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Topics: Androgen Antagonists; Androstenes; Combined Modality Therapy; Docetaxel; Humans; Lymph Node Excision; Male; Metastasectomy; Neoplasm Metastasis; Prostatic Neoplasms; Standard of Care | 2019 |
[Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer].
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Treatment Outcome | 2019 |
Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tissue Extracts | 2013 |
Recent advances revolutionize treatment of metastatic prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Benzamides; Disease-Free Survival; Hormone Replacement Therapy; Humans; Immunotherapy; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Tissue Extracts | 2013 |
Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer.
Topics: Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Interactions; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Signal Transduction; Taxoids | 2014 |
Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment.
Topics: Alpha Particles; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Cancer Vaccines; Chlorides; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Taxoids; Tissue Extracts | 2013 |
Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology.
Topics: Androgen Antagonists; Androgens; Androstenes; Androstenols; Animals; Antineoplastic Agents; Benzamides; Dehydroepiandrosterone; Endocrinology; Gonadotropin-Releasing Hormone; Humans; Male; Mutation; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Testosterone; Treatment Outcome | 2015 |
Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer.
Topics: Androstenes; Antineoplastic Agents, Hormonal; Disease Progression; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2014 |
Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents.
Topics: Aged; Androstenes; Benzamides; Health Services for the Aged; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Tissue Extracts | 2014 |
Androgen pathway resistance in prostate cancer and therapeutic implications.
Topics: Androgens; Androstenes; Benzamides; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Point Mutation; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Protein Splicing; Receptors, Androgen; Signal Transduction | 2015 |
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate; Taxoids; Tissue Extracts | 2015 |
[Hormone therapy in prostate cancer; a pharmacotherapeutic challenge].
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Disease Progression; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Testosterone; Treatment Outcome | 2015 |
What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2016 |
The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II).
Topics: Androgens; Androstenes; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Humans; Immunotherapy; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2017 |
Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Forecasting; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Failure | 2011 |
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Docetaxel; Humans; Male; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Radioisotopes; Taxoids; Tissue Extracts | 2011 |
The role of abiraterone in the management of metastatic castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials as Topic; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms | 2012 |
Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpoint.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prognosis; Prostatic Neoplasms; Survival Rate; Taxoids | 2013 |
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androstenes; Androstenols; Animals; Drug Evaluation; Humans; Lyases; Male; Mice; Neoplasm Metastasis; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase | 2005 |
Trials
24 trial(s) available for abiraterone and Neoplasm Metastasis
Article | Year |
---|---|
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Androstenes; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Benzamides; Humans; Immune Checkpoint Inhibitors; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Receptor Protein-Tyrosine Kinases | 2022 |
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Benzamides; Genes, BRCA1; Genes, BRCA2; Humans; Loss of Function Mutation; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant | 2020 |
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Treatment Outcome | 2020 |
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Benzamides; Disease-Free Survival; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Taxoids; Treatment Outcome | 2020 |
Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide.
Topics: Aged; Aged, 80 and over; Androstenes; Antigens, Surface; Benzamides; Glutamate Carboxypeptidase II; Humans; Immunoconjugates; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Treatment Failure | 2021 |
Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Models, Biological; Neoplasm Metastasis; Neoplasms; Paclitaxel; Piperazines; Prednisolone; Pyrimidines | 2021 |
Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer.
Topics: Adrenal Cortex; Adult; Aged; Aged, 80 and over; Androgens; Androstenes; Antineoplastic Agents, Hormonal; Correlation of Data; Drug Combinations; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2021 |
Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
Topics: Androstenes; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genetic Variation; Humans; Male; Neoplasm Metastasis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; RNA Interference | 2017 |
Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Benzamides; Choline; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Positron Emission Tomography Computed Tomography; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Reproducibility of Results; Retrospective Studies | 2018 |
Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer.
Topics: Androgens; Androstenes; Disease Progression; Humans; Male; Models, Theoretical; Neoplasm Metastasis; Pilot Projects; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Testosterone; Time Factors; Treatment Failure; Treatment Outcome | 2017 |
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; DNA Repair; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Poly(ADP-ribose) Polymerase Inhibitors; Prednisone; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-ets; Receptors, Androgen | 2018 |
Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Follow-Up Studies; Humans; Male; Neoplasm Metastasis; Neoplastic Cells, Circulating; Prednisone; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Survival Rate | 2018 |
Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrimidines; Treatment Outcome | 2019 |
Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life | 2019 |
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
Topics: Aged; Aged, 80 and over; Androstenes; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2019 |
External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; ROC Curve; Survival Rate; Taxoids; Time Factors | 2014 |
Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; Survival Analysis; Taxoids | 2015 |
A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome | 2015 |
High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Double-Blind Method; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Outcome Assessment, Health Care; Phenylthiohydantoin; Prognosis; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Subcutaneous Fat | 2015 |
A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Androgens; Androstenes; Disease Progression; Drug Resistance, Neoplasm; Dutasteride; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radiography; Receptors, Androgen | 2017 |
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2017 |
A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Testosterone | 2016 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Double-Blind Method; Fatigue; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Survival Analysis; Treatment Outcome | 2011 |
Other Studies
89 other study(ies) available for abiraterone and Neoplasm Metastasis
Article | Year |
---|---|
Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC).
Topics: Androstenes; Antineoplastic Agents; Benzamides; Black People; Docetaxel; Guadeloupe; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
Clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with abiraterone with or without ongoing androgen deprivation therapy: A retrospective case-control study.
Topics: Androgen Antagonists; Androstenes; Case-Control Studies; Humans; Male; Neoplasm Metastasis; Progression-Free Survival; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Taxoids | 2019 |
Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients.
Topics: Aged; Androstenes; Antigens, Surface; Benzamides; Gene Expression Regulation, Neoplastic; Glutamate Carboxypeptidase II; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2019 |
Managing lines of therapy in castration-resistant prostate cancer: real-life snapshot from a multicenter cohort.
Topics: Aged; Aged, 80 and over; Androstenes; Benzamides; Cohort Studies; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2020 |
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2019 |
Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. CON: Novel oral agents provide an attractive alternative to chemotherapy in metastatic hormone-sensitive prostate cancer.
Topics: Administration, Oral; Androstenes; Benzamides; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Thiohydantoins | 2020 |
Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience.
Topics: Aged; Aged, 80 and over; Androgen Receptor Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiosurgery; Radiotherapy, Conformal; Receptors, Androgen; Retrospective Studies; Treatment Outcome | 2019 |
Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Case-Control Studies; Circulating MicroRNA; Docetaxel; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Survival Rate | 2020 |
Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter?
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Drug Administration Schedule; Humans; Kallikreins; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2020 |
Topics: Androstenes; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2020 |
Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Benzamides; Cohort Studies; Humans; Male; Medication Adherence; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2020 |
Role of the neutrophil/lymphocyte ratio in patients with metastatic castration-resistant prostate cancer treated first-line with abiraterone.
Topics: Aged; Aged, 80 and over; Androstenes; Humans; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2020 |
Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (CRPC): a post hoc analysis of two randomized clinical trials.
Topics: Androstenes; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neoplasm Metastasis; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Vitamin D | 2020 |
Use of record linkage to evaluate treatment outcomes and trial eligibility in a real-world metastatic prostate cancer population in Scotland.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Benzamides; Clinical Decision-Making; Clinical Trials as Topic; Electronic Health Records; Eligibility Determination; Humans; Male; Medical Record Linkage; Middle Aged; Neoplasm Metastasis; Nitriles; Patient Selection; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Scotland; State Medicine; Time Factors; Treatment Outcome | 2020 |
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Denosumab; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Zoledronic Acid | 2020 |
Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Treatment Failure | 2020 |
Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Benzamides; Docetaxel; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Risk Factors; Signal Transduction; Taxoids | 2021 |
Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Body Composition; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant | 2020 |
Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience.
Topics: Aged; Aged, 80 and over; Androstenes; Combined Modality Therapy; Cytoreduction Surgical Procedures; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant | 2021 |
Antiandrogen abiraterone and docetaxel treatments affect Notch1, Jagged1 and Hes1 expressions in metastatic prostate cancer cells.
Topics: Androgen Antagonists; Androstenes; Cell Line, Tumor; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Jagged-1 Protein; Male; Neoplasm Metastasis; Prostatic Neoplasms; Receptor, Notch1; RNA, Messenger; Transcription Factor HES-1 | 2021 |
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Benzamides; Chromosomal Instability; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Neurosecretory Systems; Nitriles; Phenotype; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2021 |
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Benzamides; Biomarkers, Tumor; Cell Count; Clinical Decision-Making; Humans; Keratins; Leukocyte Common Antigens; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Predictive Value of Tests; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Reproducibility of Results | 2021 |
Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
Topics: Androstenes; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiosurgery; Treatment Outcome | 2021 |
Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options.
Topics: Androstenes; Black or African American; Docetaxel; Georgia; Health Status Disparities; Hormones; Humans; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies | 2021 |
Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Benzamides; Cognition; Drug Therapy; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2021 |
Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France.
Topics: Aged; Aged, 80 and over; Androstenes; Comorbidity; Cross-Sectional Studies; Disease-Free Survival; Drug Interactions; Electronic Health Records; Enzyme Inhibitors; France; Humans; Male; Neoplasm Metastasis; Pain; Pharmacists; Polypharmacy; Prevalence; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2017 |
Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.
Topics: Aged; Androstenes; Antineoplastic Agents; Benzamides; Cohort Studies; Disease-Free Survival; Humans; Kallikreins; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; RNA, Messenger; Treatment Outcome | 2017 |
Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D.
Topics: Aged; Androstenes; Antineoplastic Agents; Benzamides; Catchment Area, Health; Drug Prescriptions; Humans; Insurance Coverage; Male; Medical Oncology; Medicare Part D; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Practice Patterns, Physicians'; Prostatic Neoplasms, Castration-Resistant; United States; Urology | 2017 |
Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey.
Topics: Androstenes; Biomarkers, Tumor; Clinical Decision-Making; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplastic Cells, Circulating; Practice Patterns, Physicians'; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Surveys and Questionnaires; Taxoids; Treatment Outcome; Tubulin Modulators | 2018 |
Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Castration; Disease-Free Survival; Humans; Male; Neoplasm Metastasis; Prednisolone; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: a retrospective study.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2017 |
The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy.
Topics: Androgen Antagonists; Androstenes; Benzamides; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glucocorticoids; Humans; Kaplan-Meier Estimate; Male; MCF-7 Cells; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Glucocorticoid | 2018 |
Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden.
Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Cross-Sectional Studies; Drug Prescriptions; Educational Status; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Registries; Residence Characteristics; Sweden; Time Factors | 2018 |
Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Topics: Aged; Androgen Antagonists; Androstenes; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Benzamides; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Protein; Clinical Decision-Making; DNA Mutational Analysis; DNA Repair Enzymes; Genetic Predisposition to Disease; Germ-Line Mutation; GPI-Linked Proteins; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Nitriles; Phenotype; Phenylthiohydantoin; Precision Medicine; Progression-Free Survival; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Time Factors; Treatment Outcome | 2018 |
Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Anti-Inflammatory Agents; Docetaxel; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2019 |
Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease.
Topics: Androstenes; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Receptors, Androgen; Signal Transduction; Tamoxifen | 2018 |
Improving outcome in patients with prostate and kidney cancer: heading in the right direction?
Topics: Androstenes; Antineoplastic Agents; Clinical Decision-Making; Humans; Immunotherapy; Kidney Neoplasms; Male; Neoplasm Metastasis; Patient Participation; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Protein-Tyrosine Kinases | 2018 |
Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic Diseases; Dexamethasone; Disease Progression; Drug Substitution; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prognosis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2019 |
Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer.
Topics: Androstenes; Disease Management; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance; Game Theory; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life | 2018 |
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Humans; Kallikreins; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Spain; Time Factors | 2019 |
Oligometastatic Prostate Cancer Should Be Studied and Treated Differently to High-volume Disease. Con: The Underlying Biology is the Same, So They Should Not Be Treated Differently.
Topics: Androstenes; Cost of Illness; Docetaxel; Humans; Male; Molecular Biology; Neoplasm Metastasis; Phenotype; Positron-Emission Tomography; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy; Tubulin Modulators; Whole Body Imaging | 2019 |
STAMPEDE: Is Radiation Therapy to the Primary a New Standard of Care in Men with Metastatic Prostate Cancer?
Topics: Androgen Antagonists; Androstenes; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Radiation Injuries; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Standard of Care | 2019 |
Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Fasting; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant | 2019 |
Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression.
Topics: Aged; Androstenes; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Terminal Care; Treatment Outcome | 2019 |
Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Patient Selection; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Standard of Care; Tumor Burden | 2019 |
Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Computational Biology; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2019 |
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
Topics: Aged; Aldo-Keto Reductase Family 1 Member C3; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Image-Guided Biopsy; Immunohistochemistry; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2019 |
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
Topics: Active Transport, Cell Nucleus; Androstenes; Androstenols; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Nucleus; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Green Fluorescent Proteins; Humans; Male; Microscopy, Confocal; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Time-Lapse Imaging | 2013 |
New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?
Topics: Androstenes; Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Decision Trees; Drug Costs; Financing, Personal; Humans; Male; Models, Economic; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Quality-Adjusted Life Years; Survival Rate; Taxoids | 2014 |
Abiraterone and metastatic prostate cancer: delays pain onset, cytotoxic therapy, and possibly death.
Topics: Androgen Antagonists; Androstenes; Androstenols; Chemical and Drug Induced Liver Injury; Heart Diseases; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms | 2014 |
The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus.
Topics: Algorithms; Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cancer Vaccines; Humans; Immunosuppressive Agents; Ipilimumab; Lupus Erythematosus, Systemic; Male; Melanoma; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Randomized Controlled Trials as Topic; Skin Neoplasms; Tissue Extracts | 2014 |
PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Disease-Free Survival; Humans; Italy; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole.
Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2014 |
Prostate cancer: the best fit for enzalutamide in metastatic prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Patient Selection; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer.
Topics: Adult; Aged; Androstenes; Antineoplastic Agents; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms | 2015 |
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Biomarkers, Tumor; Disease-Free Survival; DNA Copy Number Variations; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation, Missense; Neoplasm Metastasis; Neoplastic Cells, Circulating; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids | 2015 |
Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Benzamides; Cell Line, Tumor; Disease Progression; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2015 |
Abiraterone in metastatic salivary duct carcinoma.
Topics: Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Humans; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Salivary Ducts; Salivary Gland Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience.
Topics: Aged; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Endpoint Determination; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Failure | 2015 |
Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Survival Analysis | 2015 |
Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Viscera | 2015 |
Treatment: When less is more.
Topics: Androstenes; Benzamides; Castration; Clinical Trials as Topic; Disease Progression; Humans; Male; Neoplasm Metastasis; Nitriles; Patient Selection; Phenylthiohydantoin; Precision Medicine; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Testosterone | 2015 |
Metastasis: Resistance fighters.
Topics: Alternative Splicing; Androgen Antagonists; Androstenes; Benzamides; DNA Repair; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Thionucleotides | 2015 |
The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
A single-center experience with abiraterone as treatment for metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2016 |
Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer.
Topics: Aged; Alkaline Phosphatase; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Disease-Free Survival; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2016 |
Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
Topics: Aged; Aged, 80 and over; Androstenes; Chromogranin A; Disease-Free Survival; Humans; Male; Middle Aged; Neoplasm Metastasis; Phosphopyruvate Hydratase; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2017 |
[Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy].
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2016 |
The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Benzamides; Disease Progression; Disease-Free Survival; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Regression Analysis; Survival Analysis; Treatment Outcome | 2016 |
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Biomarkers, Tumor; Docetaxel; Follow-Up Studies; Humans; Italy; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2016 |
Bilateral Choroidal Metastases from Prostate Cancer revealed in a patient under Abiraterone - Fourteen years after diagnosis.
Topics: Androstenes; Antineoplastic Agents; Disease Progression; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2016 |
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Clinical Trials as Topic; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Multivariate Analysis; Neoplasm Metastasis; Neoplastic Cells, Circulating; Prednisone; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant | 2016 |
Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide.
Topics: Androstenes; Benzamides; Biomarkers; Bridged-Ring Compounds; Cost Savings; Costs and Cost Analysis; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Taxoids | 2016 |
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; RNA | 2017 |
Comment on: "Modeling the Relationship between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer".
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2017 |
An exploratory analysis of the association between levels of hormones implied in steroid biosynthesis and activity of abiraterone in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents, Hormonal; Hormones; Humans; Male; Middle Aged; Neoplasm Metastasis; Predictive Value of Tests; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroids; Treatment Outcome | 2017 |
The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.
Topics: Aged; Androstenes; Antineoplastic Agents; Humans; Kaplan-Meier Estimate; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2017 |
[Concomitant use of abiraterone acetate and triptorelin in patients with castration-resistant prostate cancer].
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Triptorelin Pamoate | 2016 |
New findings in bladder and prostate cancer: highlights from the 26th annual congress of the European Association of Urology, March 18-22, 2011, Vienna, Austria.
Topics: Androstenes; Androstenols; Biomarkers; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Pelvis; Prostatectomy; Prostatic Neoplasms; Radioimmunotherapy; Urinary Bladder Neoplasms | 2011 |
Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Cancer Vaccines; Clinical Trials, Phase III as Topic; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Taxoids | 2011 |
Expanding treatment options for metastatic prostate cancer.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase | 2011 |
Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Enzyme Inhibitors; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostatic Neoplasms | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Taxoids | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Adrenocorticotropic Hormone; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase | 2011 |
Abiraterone. After prostate cancer treatment failure: 4-month survival advantage.
Topics: Androstenes; Androstenols; Drug Interactions; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms | 2012 |
Abiraterone and its place in the treatment of metastatic CRPC.
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Castration; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2013 |